A phase II study of octreotide in metastatic advanced prostatic cancer (MAPC)
A. Tucci(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), G Pacilio, Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giacomo Cartenì(Ospedale Antonio Cardarelli), M. Biglietto(Ospedale Antonio Cardarelli), G.P. Nicolella(Radiation Oncology Institute)
Cited by 2
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180